STS-135 (drug)

STS-135 is a synthetic cannabinoid that is also a designer drug. It was first detected in smoking products in Japan in 2012. The drug is named after the Space Shuttle Atlantis's final mission, STS-135.

Chemistry

STS-135 is a derivative of Adamantane, a synthetic diamond. It is part of the naphthoylindole family, which also includes JWH-018 and AM-2201. These are all cannabinoid receptor agonists. STS-135 is a CB1 receptor agonist, which is the same receptor that THC, the main active ingredient in cannabis, binds to.

Effects

The effects of STS-135 are similar to those of other synthetic cannabinoids and include euphoria, relaxation, and altered perception. However, it also has a number of negative effects, including anxiety, paranoia, and psychosis. It is also associated with a number of health risks, including tachycardia, hypertension, and seizures.

Legal Status

STS-135 is illegal in many countries, including the United States, where it is classified as a Schedule I drug. It is also illegal in the United Kingdom, where it is classified as a Class B drug.

See Also

• Synthetic cannabinoids
• Designer drugs
• Adamantane
• Naphthoylindole
• Cannabinoid receptor
• CB1 receptor
• THC
• Cannabis
• Euphoria
• Relaxation
• Altered perception
• Anxiety
• Paranoia
• Psychosis
• Tachycardia
• Hypertension
• Seizures
• Schedule I drug
• Class B drug

STS-135 (drug) Resources
Latest articles Most recent articles Ongoing trials	Wikipedia